Objective. The acronym MRONJ has been created in order to identify "Medication-Related Osteonecrosis of the Jaw," observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in a Chron's disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case. On August, 2014, a 63-year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from 2010 to 2013 presented referring pain in the right mandible. Results. This patient presented with nonexposed osteonecrosis of the jaw after placement, on September, 2010, of four titanium fixtures in the mandible. Conclusions. The authors suggest that the biologic therapy with an anti-TNF-alpha antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.

Adalimumab: another medication related to osteonecrosis of the jaws? / Cassoni, Andrea; Romeo, Umberto; Terenzi, Valentina; Della Monaca, Marco; Rajabtork Zadeh, Oriana; Raponi, Ingrid; Fadda, Maria Teresa; Polimeni, Antonella; Valentini, Valentino. - In: CASE REPORTS IN DENTISTRY. - ISSN 2090-6447. - ELETTRONICO. - 2016:(2016), pp. 1-6. [10.1155/2016/2856926]

Adalimumab: another medication related to osteonecrosis of the jaws?

Cassoni, Andrea
Primo
;
Romeo, Umberto
Secondo
;
Terenzi, Valentina
;
Della Monaca, Marco;Rajabtork Zadeh, Oriana;Raponi, Ingrid;Fadda, Maria Teresa;Polimeni, Antonella
Penultimo
;
Valentini, Valentino
Ultimo
2016

Abstract

Objective. The acronym MRONJ has been created in order to identify "Medication-Related Osteonecrosis of the Jaw," observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in a Chron's disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case. On August, 2014, a 63-year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from 2010 to 2013 presented referring pain in the right mandible. Results. This patient presented with nonexposed osteonecrosis of the jaw after placement, on September, 2010, of four titanium fixtures in the mandible. Conclusions. The authors suggest that the biologic therapy with an anti-TNF-alpha antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.
File allegati a questo prodotto
File Dimensione Formato  
Cassoni_Adalimumab_2016.pdf

accesso aperto

Note: https://www.hindawi.com/journals/crid/2016/2856926/
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.52 MB
Formato Adobe PDF
2.52 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/870277
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 25
social impact